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Abstract
High fructose feeding causes diet-induced alterations of lipid metabolism and decreased insulin
sensitivity, hallmark of which is a rapid and profound hypertriglyceridemia. One of the mechanisms
that contribute to serum hypertriglyceridemia in this model is suppression of hepatic PPARα.
HMG-CoA inhibitors, which reduce serum triglycerides in these animals, also elevate/restore
hepatic PPARα. Previously we demonstrated that two known lipoxygenase/cyclooxygenase
inhibitors reversed diet-induced hypertriglyceridemia in this model and that reversal of certain
inflammatory markers in the liver correlated with the metabolic benefit. In this paper we extended
these studies by examining the impact of these compounds on expression of PPARα, both at the
level of transcription and expression. Our data show that diet-induced suppression of hepaic
PPARα is reversed upon treatment with lipoxygenase/cyclooxygenase compounds. We then tested
one of these compounds, BW-755c, over a range of doses from 10 mg/kg to 100 mg/kg to establish
a dose-response relationship with the reduction of serum hypertriglyceridemia in this model. These
experiments support the concept of using anti-inflammatory medications as one method to correct
metabolic dysfunction.
Background
Recent epidemiological studies have shown that almost a
quarter of adults in the United States have metabolic syn-
drome or syndrome X and prevalence of this syndrome is
increasing world-wide owing to lifestyle changes leading
to obesity [1-3]. A cluster of abnormalities define meta-
bolic syndrome including insulin resistance, hypertriglyc-
eridemia, low high-density lipoprotein (HDL)
cholesterol, obesity and hypertension [4-6]; individuals
with syndrome have an increased risk of developing cardi-
ovascular disease [5,6]. Insulin resistance is now consid-
ered a central factor among these various abnormalities
associated with the metabolic syndrome. With this in
mind, much effort is being invested in improving the
insulin resistance through lifestyle modification (e.g.,
weight reduction, dietary interventions, and increased
physical activity) and development of new therapeutic
agents that sensitize insulin action, ameliorate hypertrig-
lyceridemia, raise HDL levels and improve hypertension
[2,7-12].
In an animal model, high fructose fed (HFF) diets induce
metabolic dysfunction typically resulting in a rapid eleva-
tion of serum triglycerides with a corresponding increase
in blood pressure within two weeks of diet intitiation.
Animals maintained on this diet for longer periods of
time develop elevated free fatty acids and hyperinsuline-
mia at the expense of glycemic control. If HFF animals are
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subjected to an exercise regimen, the diet-induced effects
can be ameliorated [13]. Thus this animal model exhibits
an early stage of the Metabolic Syndrome in which a com-
bination of physical inactivity and diet results in cardio-
vascular disease and metabolic complications.
High fructose corn sweeteners began widespread use in
the food industry in 1967. Since that time the amount of
fructose consumption has steadily risen and now accounts
for about 9% of daily caloric intake in the United States.
Unlike glucose, which is widely utilized by tissues
throughout the body, fructose is primarily metabolized in
the liver [14,15]. Recent epidemiological data suggests
that high fructose corn sweeteners may be contributing to
the overall epidemic of obesity and metabolic disease in
the US [16].
We initiated studies to test the effects of lipoxygenase/
cyclooxygenase inhibitors on the metabolic and hepatic
status of HFF rats. We examined two structurally different
LOX/COX inhibitors because NDGA, which has previ-
ously demonstrated effects in this model [17], also exhib-
its numerous other biological effects. In an initial report
we showed that high levels of dietary fructose induced the
JNK/AP-1 stress response pathway. This observation was
confirmed by Wei and Pagliassotti, who correlated fruc-
tose-induced JNK activity with hepatic insulin resistance
[18]. In our first report, we focused on the correlation
between normalization of the stress response pathway
and reduction of serum triglycerides. In this report, we
expanded these studies to examine diet-induced effects on
hepatic peroxisome proliferators-activated receptor α
(PPARα) activity and the relationship between LOX/COX
inhibitor treatment and of PPARα expression.
PPARα (NR1C1) is a ligand (lipid)-activated transcription
factor that belongs to the superfamily of nuclear receptor
[19-22]. In addition to PPARα, the NR1C subset of recep-
tors includes two closely related members, PPARβ (or δ,
NR1C2) and PPARγ (NR1C3). PPARα is highly expressed
in the liver, cardiac muscle, intestine and renal cortex tis-
sues [19,23], serves an essential function in the regulation
of lipid metabolism and controls the expression of a
number of genes involved in mitochondrial and peroxiso-
mal β-oxidation [19-22]. It increases gene transcription by
binding as a heterodimer with retinoid X receptor (RXR)
to PPAR response elements (PPRE) on the promoter
regions of the target gene [22]. Activators of PPARα, such
as fibrates, lower circulating levels of lipid and are com-
monly used to treat hypertriglyceridemia [21,22,24].
More recent studies have shown an inverse relationship
between PPAR activity and abnormalities in fatty acid
metabolism leading to the development of insulin resist-
ance and alterations in glucose metabolism [25-27]. In
addition, animal studies suggest that that the activation of
PPARα improved the insulin resistance that was triggered
by the excessive production and accumulation of lipids
[28-32].
Our studies indicate hypertriglyceridemia induced by
fructose feeding greatly reduces the hepatic expression of
both PPARα protein and mRNA levels. We further dem-
onstrate that diet-induced suppression of hepaic PPARα is
reversed upon treatment with lipoxygenase/cyclooxygen-
ase inhibitory compounds. Our findings also suggest that
these compounds to some extent also up-regulated the
mRNA levels of ubiquitous PPARβ/δ. From these studies,
we conclude that anti-inflammatory agents have the
potential to prevent or treat multiple aspects of the meta-
bolic syndrome.
Methods
Animals and treatments
Male Sprague-Dawley rats weighing approximately 180–
200 g first maintained on a rat chow diet and then were
divided into 6 groups and were switched to a high-fruc-
tose diet (TD89247; Harlan Teklad, Madison, WI) that
provided 60% of total calories as a fructose (Day 1). On
day 15 of treatment, the rats were fasted for 4 hours and
tail vein blood was collected for baseline measurements
of serum TG, glucose, insulin and free fatty acids (FFA) as
previously described [33]. The groups of rats were then
treated with either vehicle (0.5% carboxymethyl cellu-
lose) or BW755c (suspended 0.5% carboxymethyl cellu-
lose) at one of several doses ranging from 5 mg/kg to 100
mg/kg. The vehicle group and most groups receiving BW-
755c or NDGA (250 mg/kg) were treated twice a day
(b.i.d.) for 4 days, delivered by oral gavage i.e., animals
were treated with vehicle or drug at day 0 at 4:00 PM, at
day 1 at 9:00 AM and 4:00 PM, at day 2 at 9:00 AM and
4:00 PM, at day 3 at 9:00 AM and 4:00 PM and at day 4 at
9:00 AM. In addition, one group of animals was treated
with 50 mg/kg BW-755c once a day (q.d.) at 9:00 AM by
oral gavage. During the treatment regimen the animals
were maintained on high-fructose diet. On the last day
(day 4), animals were fasted for 4 h (8:00 AM-12:00 PM)
and blood was collected from the tail vein 3 hours after
last dose (i.e., 9:00 AM to 12:00 PM) and serum samples
analysed for TG, glucose, insulin, FFA, and total choles-
terol [33-35]. After the serum was collected, the animals
were sacrificed and tissues removed, snap-frozen in liquid
nitrogen and stored at -80°C until analysed. The local
committee on animal care approved all animal protocols.
RNA isolation and reverse transcription
The liver samples used in these studies were derived from
animals treated as previously described [36].
Total RNA was extracted from the liver samples (~100–
120 mg) using the Trizol reagent (Invitrogen) accordingNutrition & Metabolism 2005, 2:18 http://www.nutritionandmetabolism.com/content/2/1/18
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to the protocols recommended by the manufacturer. Sub-
sequently, purified RNA preparations were treated with
DNAse (to eliminate the possible contamination of the
genomic DNA) and further cleaned using Rneasy spin col-
umn (Qiagen, Valencia, CA). The integrity of the purified
total RNA samples to be used in the Real-time PCR assays
was confirmed by 1.2% formaldehyde-agarose gel electro-
phoresis. No degradation or 28S and 18S rRNA was
observed following staining gels with ethidium bromide.
First strand cDNAs were generated from total RNA sam-
ples as follows: 2.0 µg each of total RNA sample was dena-
tured for 5 min at 65°C in the presence random hexamer,
snap cooled in ice water, then reverse transcribed in 100
µl using the TaqMan Reverse Transcription Kit (Applied
Biosystems, Foster City, CA) according to the manufac-
turer's instructions.
Quantitative Real-time PCR measurements
Quantitative real-time PCR (Q-PCR) amplications were
performed in triplicate using the GenAmp Sequence
Detection System (Applied Biosystems). The incubation
mixture in a final volume of 50-µl contained suitable aliq-
uot of template (cDNA or RNA), 300 nM each of forward
and reverse primers for PPARα or 18S ribosomal RNA and
1X SYBR® Green PCR Master Mix (Applied Biosystems) in
50-µl. Gene-specific primers were designed for rat PPARα
gene and 18S rRNA using Primer Express software
(Applied Biosystem) using sequences accessed through
GenBank. The primer sequences are as shown in Table 1.
Samples were amplified in an ABI Prism™ 7700 Sequence
Detection System (Applied Biosystems). The change in
fluorescence of SYBR® Green I dye in every cycle was mon-
itored, and threshold cycle (CT) above background for
each reaction (i.e., the partial cycle at which statistically
significant increases in either the PPARα or 18S rRNA first
detected) was calculated. The calculated CT  values for
PPARα in response to various treatments were normalized
to the respective CT values for 18S rRNA and expressed as
'Relative Values'. Initially, post-amplification melting
curves and gel-electrophoresis analyses were performed to
confirm that a single PCR product was produced in each
reaction. The contribution of contaminating genomic
DNA to the observed product in each case was determined
from the CT given by RNA template. These values usually
ranged less than 0.1% of cDNA values.
Western Blot analysis of hepatic PPARα
Liver samples (~200 mg) were homogenized using a Pot-
ter-Elvehjem homogenizer in 3 volumes of detergent con-
taining lysis buffer [20 mM HEPES, pH 7.4, 1% Triton X-
100 (v/v), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 20
mM NaF, 20 mM β-glycerophosphate, 10 mM sodium
pyrophosphate, 1 mM sodium vanadate, 10 nM okadaic
acid, 1 mM dithiothreitol, 10 µg/ml aprotenin, 10 µg/ml
leupeptin, 10 µg/ml pepstatin A, 0.5 mM 4-(2-aminoe-
thyl)benzylsulfonyl fluorid (AEBSF, Roche Molecular Bio-
chemicals), 10 µM E-64 and 50 µM Bestatin] and
incubated for 30 min at 4°C on an orbital shaker for com-
plete lysis. The lysates were cleared by centrifugation at
15,000 × g for 10 min, the protein concentration of each
solubilized lysate was determined and samples stored fro-
zen until analyzed.
Samples containing an equal amount of protein (50 – 60
µg) were fractionated by SDS-polyacrylamide gel electro-
phoresis (10% polyacrylamide gel with 4% stacking gel)
and transferred to polyvinyllidene difluoride membrane
(Immobilon™, Millipore Corp., Bedford, MA). After trans-
fer the membranes were stained with Ponceau S dye
(Sigma Chemical Co. St. Louis, MO) to verify loading
equivalency and transfer efficiency and then the mem-
brane was washed in TBS containing 0.1% Tween-20
(TTBS) and incubated in blocking buffer (TTBS containing
Table 1: Gene-specific primer used for Real Time RT-PCR assays
GenBank Accession Number Primer Sequence (5'→3') Amplicon Size (bp) Region of Gene (nt)
NM_013196 Rat PPARα 177
Forward 
TCACACAATGCAATCCGTTT
876–895
Reverse 
GGCCTTGACCTTGTTCATGT
1052–1033
V01279 Rat 18S rRNA 133
Forward 
ATGGCCGTTCTTAGTTGGTG
1336–1355
Reverse 
AACGCCACTTGTCCCTCTAA
1468–1449
Primer sequences were designed using Primer Express software (Applied Biosystems) using sequences accessed through GenBank. Amplicon size 
and region of each gene are indicated.Nutrition & Metabolism 2005, 2:18 http://www.nutritionandmetabolism.com/content/2/1/18
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5% non-fat dry milk) for 90 min at room temperature fol-
lowed by overnight incubation at 4°C with rabbit anti-
PPARα IgG (Santa Cruz Biotechnology, Santa Cruz, CA)
diluted in blocking buffer. Subsequently, the membrane
was washed in TTBS and incubated for 2 hr with horserad-
ish peroxidase conjugated goat anti-rabbit IgG (Sigma
Chemical Co. St. Louis, MO) in blocking buffer. Bands
were visualized by enhanced chemiluminescence detec-
tion as described by the manufacturer (ECL System, Amer-
sham Pharmacia Biotech). Blots were exposed to film for
various times (3–10 min), and exposures were subjected
to densitometric scanning using Fluor-S™ MultiImager
with a built-in computer software (Bio-Rad). Equal load-
ing of proteins was confirmed by staining the membranes
with the Ponsceau S.
Statistical Analysis
Dose response analysis was conducted using paired t-tests.
PPARα RT-PCR and Western Blots were analyzed using t-
test comparing the drug treatment group to the vehicle
control. All statistical analyses were performed using
GraphPad Prism version 3.00 for Windows, GraphPad
Software, San Diego California USA, http://www.graph
pad.com.
Results
Dose-responsive reduction of diet-induced 
hypertriglyceridemia
Table 2 summarizes the effect of 4 consecutive day's treat-
ment using BW-755c on HFF animals. During the treat-
ment phase no obvious toxic effects were noted in the
animals. All animals at all dose groups gained weight dur-
ing the testing period. In these animals there was no dis-
cernable hyperinsulinemia or elevated FFA. The only
metabolic effect in this group of animals was hypertriglyc-
eridemia. BW-755c lowered serum triglycerides in a dose-
related fashion (Figure 1). In addition, there was no differ-
ence between dosing the animals once daily versus twice
daily as can be appreciated by comparing the 20 mg/kg
bid (40 mg/kg daily) results versus the 50 mg/kg qd
groups. There were no changes in any of the other meas-
ured metabolic parameters during the test period.
BW-755c treatment restores PPARα protein levels in HFF 
animals
Figure 2 shows that the amount of hepatic PPARα protein
is reduced upon initiation of the HFF diet. Each lane rep-
resents a liver sample from a different animal in the dos-
ing group. This was done to control for variation due to
unrestricted feeding of the animals and it's potential
impact on the expression of PPARα and to ensure that the
observed responses were generalized to the group and not
an animal-specific observation. Liver samples from chow-
fed animals were included as a control group because they
represent normal expression levels of PPARalpha. Liver
samples from the group of vehicle treated HFF animal
Table 2: Dose-responsive effect of BW-755c on hypertriglyceridenia in HFF rats
HFF Day 15 n = 24 Vehicle n = 4 5 mg/kg BW 
(b.i.d.) n = 4
10 mg/kg BW 
(b.i.d.) n = 4
20 mg/kg BW 
(b.i.d.) n = 4
50 mg/kg BW 
(b.i.d.) n = 4
50 mg/kg BW 
(q.d.) n = 4
Weight (g) 301 ± 2.3 312 ± 8a 312 ± 7a 312 ± 5d 310 ± 5a 316 ± 6b 317 ± 6c
Glucose (mg/dl) 116.0 ± 1.6 113.0 ± 3.4 113.8 ± 6.4 115.3 ± 5.1 112.8 ± 2.9 115.5 ± 8.7 119.3 ± 7.0
Insulin (ng/ml) 1.84 ± 0.06 1.78 ± 0.13 1.83 ± 0.13 1.86 ± 0.15 1.77 ± 0.09 1.82 ± 0.05 1.81 ± 0.13
FFA (µEq/l) 532 ± 17 553 ± 54 552 ± 63 543 ± 92 528 ± 32 562 ± 39 540 ± 52
Cholesterol (mg/dl) 109.6 ± 1.5 106.8 ± 5.8 109.5 ± 6.4 105.0 ± 3.5 107.8 ± 2.8 109.0 ± 4.1 113.3 ± 3.2
TG (mg/dl) 367 ± 16 351 ± 31 319 ± 59 268 ± 18 216 ± 17a 154 ± 33a 215 ± 39a
Results are Mean ± SE
ap < 0.001; bp < 0.002; cp < 0.004; dp < 0.04
Dose-responsive reduction of serum triglycerides upon  treatment with BW-755c (mean +/- SD) Figure 1
Dose-responsive reduction of serum triglycerides 
upon treatment with BW-755c (mean +/- SD). The 
statistical significance of each of the dose groups is shown in 
Table 2.Nutrition & Metabolism 2005, 2:18 http://www.nutritionandmetabolism.com/content/2/1/18
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represent the expected degree of diet-induced PPARalpha
suppression. Liver samples from HFF animals that were
treated with either NDGA or BW-755c demonstrate nor-
mal or elevated levels of PPARα protein (Table 3). This
data shows that these compounds are able to overcome
the diet induced suppression either directly or by a com-
pensatory mechanism.
BW-755c treatment restores PPARα RNA expression in 
HFF animals
In order to determine the mechanism by which the HFF
diet suppressed PPARa we measured the relative amount
of PPARα RNA in the livers of the animal in the various
treatment groups. As seen in Table 4, PPARα RNA is sup-
pressed in HFF animals, indicating that the method of
control is related to transcription rather than protein
expression. The LOX/COX drug treatment increased
PPARα RNA levels. In the case of BW-755c the relative
amounts of RNA were comparable to that of the vehicle
control. NDGA treatment resulted in higher levels of
PPARα RNA. This may be a secondary effect of this com-
pound because hepatic RNA levels of PPARβ/δ were also
elevated in response to this drug (data not shown).
Discussion
There is building evidence that improper consumption of
metabolic components, including fatty acids and carbo-
hydrates, can lead to systemic inflammation. This sys-
temic inflammation is at least contributory, if not
causative, to metabolic disease progression.
The early stage of the HFF model is useful to examine dis-
lipidemia because the animals lack many confounding
factors such as insulin resistance or the impact of elevated
FFA or obesity. In the earliest stage of metabolic dysfunc-
tion, these animals receive excess dietary fructose and
exhibit hypertriglyceridemia. Hepatic fructose metabo-
lism leads to precursors of triglyceride synthesis and thus
it is not altogether surprising that dietary fructose leads to
generation of triglycerides. Clearly, however the compen-
satory metabolic regulatory mechanisms are disrupted in
these animals because they fail to control triglycerides
within normal ranges. In our prior work, we showed a cor-
relation between activation of the JNK stress pathway
leading to activation of the transcription factor AP-1 and
abnormal triglyceride levels. We also showed that LOX/
COX inhibitors inhibited the JNK/AP-1 activation and
correspondingly reduced serum triglyceride levels even in
the face of excess dietary fructose.
Representative Western blots for PPARα expression in hepatic tissue from chow-fed (control) rats and high fructose-fed rats  that were subsequently treated with vehicle alone, NDGA or BW755c Figure 2
Representative Western blots for PPARα expression in hepatic tissue from chow-fed (control) rats and high 
fructose-fed rats that were subsequently treated with vehicle alone, NDGA or BW755c. Each lane represents 
hepatic tissue from each of four different animals in each group.Nutrition & Metabolism 2005, 2:18 http://www.nutritionandmetabolism.com/content/2/1/18
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In this paper we extend this correlation to the expression
of PPARα, in which excess dietary fructose suppresses
PPARα but such suppression can be overcome by admin-
istration of these LOX/COX inhibitory compounds. The
PPARα is lipid activated transcription factor that plays a
pivotal role in the transcription regulation of genes
involved in lipid catabolism and lipoprotein metabolism.
In hepatocytes and other tissues (e.g., heart) natural long
chain fatty acids (ligand) activated PPARα binds to perox-
isome proliferators response element (PPRE) of DNA and
increases the transcription of genes encoding enzymes
involved in fatty acid oxidation (e.g., acyl-CoA oxidase
and carnitine palmitoyltransferase) and lipoprotein (HDL
and VLDL/TG) metabolism (e.g., apo-AI, AII, AV, CIII,
and PTP and LPL) [19,37,38]. The out come is an increase
in hepatic fatty acid oxidation and ketogenesis, decreased
tissue levels of lipids and protection against lipotoxicity.
Our present data suggest that expression of PPARα activity
is primarily regulated at the level of transcription as deter-
mined by comparing RNA levels of hepatic PPARα in
chow-fed versus HFF animals. The fact that the LOX/COX
inhibitors resulted in restored levels of hepatic PPARα
RNA suggests that these compounds are influencing sig-
nalling pathways that regulate PPARα transcription. Beier
et al have shown that TNFα downregulates expression of
hepatic PPARα RNA [39]. We and others have demon-
strated that the HFF diet induces a TNFα-like stress
response through the JNK pathway [18,36]. Therefore a
likely mechanism by which hypertriglyceridemia is elic-
ited in the HFF model is as follows:
1. Consumption of high levels of dietary fructose leads to
activation of the JNK/AP-1 stress response pathway.
2. The activation of the stress response suppresses PPARα
expression in the liver;
3. Suppression of PPARα disrupts normal lipid homeosta-
sis and metabolism;
4. The metabolism of fructose leads to an abundance of
TG precursors that provide a source for TG synthesis; and
5. The fructose-mediated stress response may increase the
expression of sterol regulatory element-binding protein-
1c (SREBP-1c) [40,41], which activates the genes involved
Table 3: Quantitative Western blot/densitometric analysis of hepatic PPARα protein levels
Diet Treatment PPARα level (Mean ± SE)
Normal Chow Vehicle 0.149 ± 0.025
HFF Vehicle 0.038 ± 0.005a
HFF NDGA-250 mg/kg (b.i.d.) 0.290 ± 0.050b
HFF BW-755c-100 mg/kg (b.i.d.) 0.190 ± 0.030c
Results are Mean ± SE of four different samples
ap < 0.004 Chow vs HFF
bp < 0.003 HFF vs HFF/NDGA treatment
cp < 0.003 HFF vs HFF/BW-755c treatment
Table 4: Real-Time RT-PCR analysis of PPARα gene expression in liver tissue from chow-fed (control), and high fructose-fed animals 
treated with vehicle, NDGA or BW-755c
Diet Treatment PPARα normalized to 18S rRNA (Relative 
value ± SE)
Normal Chow Vehicle 2.375 ± 0.576
HFF Vehicle 0.425 ± 0.085a
HFF NDGA-250 mg/kg (b.i.d.) 3.600 ± 0.339b
HFF BW-755c-100 mg/kg (b.i.d.) 2.150 ± 0.417c
Results are Mean ± SE of four different samples
ap < 0.01 Chow vs HFF
bp < 0.001 HFF vs HFF/NDGA treatment
cp < 0.001 HFF vs HFF/BW-755c treatmentNutrition & Metabolism 2005, 2:18 http://www.nutritionandmetabolism.com/content/2/1/18
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in this seems to be unlikely possibility given the fact the
cytokine TNFα is known to negatively regulate SREBP-1c
expression [42,43] and that expression of lipogenic
enzymes is also achieved through an SREBP-1c independ-
ent mechanism [44].
With this as a working model, the mechanism by which
the LOX/COX inhibitors could act would be by their anti-
inflammatory actions in the TNFα pathway. By preventing
activation of the stress response pathways, PPARα levels
are not suppressed and therefore lipid homeostasis would
not be disrupted. Therefore the excess fructose can be nor-
mally metabolized in other ways, such as being shunted
into gluconeogenesis pathways.
Conclusion
The current studies indicate that hypertriglyceridemia
induced by high fructose feeding leads to major reduction
in the steady-state levels of both PPARα protein and
mRNA. Treatment with lipoxygenase/cyclooxygenase
inhibitor compounds reversed the fructose-induced sup-
pression of hepatic PPARa expression. These compounds
also up-regulated mRNA levels of ubiquitous PPAR iso-
form, PPARβ/δ. These anti-inflammatory agents have the
therapeutic potential in the prevention and/or manage-
ment of various aspects of the metabolic syndrome.
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